As the FDA has approved IFN-based therapies for multiple sclerosis (English and Aloi, 2015) in the U.S., treatment with IFN-β (Betaseron, Extavia), which has direct and indirect effects on tumor inhibition, will soon be utilized as a new therapeutic strategy for cancer (Borden, 2019). Here, IFNB1 is linked to neoplasm.